Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with ...

Johnson & Johnson (NYSE:JNJ), the worldwide leader in multiple myeloma, today announced new data from the investigational Phase 3 MajesTEC-3 study that demonstrate the potential of TECVAYLI® ...

IRIS Software Group Launches AI-powered Tax Anomaly Detection Tool Built on Microsoft Foundry

IRIS Software Group (IRIS), a leading global provider of accounting, HR, payroll, and education software, has launched the ...
Scientific Research Publishing

Successful Application of the Sperm Tail Flexibility Test for Immotile but Viable Sperm from a Cryopreserved Retrograde Ejaculate ()

Ahmad, K. , Prien, S. , Penrose, L. and Suh, B. (2026) Successful Application of the Sperm Tail Flexibility Test for Immotile ...
Le Lézard

Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)

Genmab A/S today announced new and updated data from three arms of the ongoing Phase 1b/2 EPCORE® CLL-1 trial (NCT04623541) evaluating the efficacy and safety of epcoritamab-bysp, a T-cell engaging ...